Cognition Therapeutics Inc
NASDAQ:CGTX

Watchlist Manager
Cognition Therapeutics Inc Logo
Cognition Therapeutics Inc
NASDAQ:CGTX
Watchlist
Price: 0.239 USD -3.86% Market Closed
Market Cap: 14.8m USD

Profitability Summary

Cognition Therapeutics Inc's profitability score is 27/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score
27/100
Profitability
Score

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Cognition Therapeutics Inc

Revenue
0 USD
Operating Expenses
-53.6m USD
Operating Income
-53.6m USD
Other Expenses
20.3m USD
Net Income
-33.3m USD

Margins Comparison
Cognition Therapeutics Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
Cognition Therapeutics Inc
NASDAQ:CGTX
14.8m USD N/A N/A
US
Eli Lilly and Co
NYSE:LLY
699.1B USD
40%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
373.4B USD
26%
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK
45%
35%
CH
Roche Holding AG
SIX:ROG
211.2B CHF
33%
14%
CH
Novartis AG
SIX:NOVN
184.2B CHF
33%
24%
UK
AstraZeneca PLC
LSE:AZN
166.2B GBP
24%
14%
US
Merck & Co Inc
NYSE:MRK
193.3B USD
34%
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
11%
-126%
US
Pfizer Inc
NYSE:PFE
133.5B USD
27%
13%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Cognition Therapeutics Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Cognition Therapeutics Inc
NASDAQ:CGTX
14.8m USD
-162%
-107%
-256%
-1 579%
US
Eli Lilly and Co
NYSE:LLY
699.1B USD
78%
14%
38%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
373.4B USD
30%
12%
18%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK
88%
27%
70%
30%
CH
Roche Holding AG
SIX:ROG
211.2B CHF
27%
9%
29%
20%
CH
Novartis AG
SIX:NOVN
184.2B CHF
33%
13%
26%
18%
UK
AstraZeneca PLC
LSE:AZN
166.2B GBP
20%
7%
18%
14%
US
Merck & Co Inc
NYSE:MRK
193.3B USD
39%
16%
25%
19%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
133.5B USD
9%
4%
10%
9%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less